Evidence map›Paper›PMID 29394276›Full record

ArticlePloS one2018

Lactobacillus gasseri CRISPR-Cas9 characterization In Vitro reveals a flexible mode of protospacer-adjacent motif recognition.

Emily M Anderson, Shawn McClelland, Elena Maksimova, Žaklina Strezoska, Megan Basila, Alexandra E Briner, Rodolphe Barrangou, Anja van Brabant Smith

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emily M AndersonDharmacon, a Horizon Discovery Group Company, Lafayette, CO, United States of America.
Shawn McClellandDharmacon, a Horizon Discovery Group Company, Lafayette, CO, United States of America.
Elena MaksimovaDharmacon, a Horizon Discovery Group Company, Lafayette, CO, United States of America.
Žaklina StrezoskaDharmacon, a Horizon Discovery Group Company, Lafayette, CO, United States of America.
Megan BasilaDharmacon, a Horizon Discovery Group Company, Lafayette, CO, United States of America.
Alexandra E BrinerDepartment of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC, United States of America.
Rodolphe BarrangouDepartment of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC, United States of America.
Anja van Brabant SmithDharmacon, a Horizon Discovery Group Company, Lafayette, CO, United States of America.ORCID 0000-0003-3145-6599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the CRISPR-Cas9 system from S. pyogenes is a powerful genome engineering tool, additional programmed nucleases would enable added flexibility in targeting space and multiplexing. Here, we characterized a CRISPR-Cas9 system from L. gasseri and found that it has modest activity in a cell-free lysate assay but no activity in mammalian cells even when altering promoter, position of tag sequences and NLS, and length of crRNA:tracrRNA. In the lysate assay we tested over 400 sequential crRNA target sequences and found that the Lga Cas9 PAM is NNGA/NDRA, different than NTAA predicted from the native bacterial host. In addition, we found multiple instances of consecutive crRNA target sites, indicating flexibility in either PAM sequence or distance from the crRNA target site. This work highlights the need for characterization of new CRISPR systems and highlights the non-triviality of porting them into eukaryotes as gene editing tools.

Indexed as

CRISPR-Cas SystemsLactobacillus gasseriRNA Editing

Identifiers

PMID29394276
PMCPMC5796720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.